The Prevalence and Economic Impact of Low-Enrolling Clinical Studies at an Academic Medical Center

被引:81
作者
Kitterman, Darlene R. [1 ]
Cheng, Steven K. [2 ]
Dilts, David M. [2 ,3 ]
Orwoll, Eric S.
机构
[1] Oregon Hlth & Sci Univ, Investigator Support & Integrat Serv, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ, Div Management, Portland, OR USA
关键词
TRANSLATIONAL SCIENCE AWARDS; TRIAL DEVELOPMENT;
D O I
10.1097/ACM.0b013e3182306440
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Purpose The authors assessed the prevalence and associated economic impact of low-enrolling clinical studies at a single academic medical center. Method The authors examined all clinical studies receiving institutional review board (IRB) review between FY2006 and FY2009 at Oregon Health & Science University (OHSU) for recruitment performance and analyzed them by type of IRB review (full-board, exempt, expedited), funding mechanism, and academic unit. A low-enrolling study included those with zero or one participant at the time of study termination. The authors calculated the costs associated with IRB review, financial setup, contract negotiation, and department study start-up activities and the total economic impact on OHSU of low-enrolling studies for FY2009. Results A total of 837 clinical studies were terminated during the study period, 260 (31.1%) of which were low-enrolling. A greater proportion of low-enrolling studies were government funded than industry funded (P = .006). The authors found significant differences among the various academic units with respect to percentages of low-enrolling studies (from 10% to 67%). The uncompensated economic impact of low-enrolling studies was conservatively estimated to be nearly $ 1 million for FY2009. Conclusions A substantial proportion of clinical studies incurred high institutional and departmental expense but resulted in little scientific benefit. Although a certain percentage of low-enrolling studies can be expected in any research organization, the overall number of such studies must be managed to reduce the aggregate costs of conducting research and to maximize research opportunities. Effective, proactive interventions are needed to address the prevalence and impact of low enrollment.
引用
收藏
页码:1360 / 1366
页数:7
相关论文
共 16 条
[1]   Linking Scientific Discovery and Better Health for the Nation: The First Three Years of the NIH's Clinical and Translational Science Awards [J].
Califf, Robert M. ;
Berglund, Lars .
ACADEMIC MEDICINE, 2010, 85 (03) :457-462
[2]   APPLYING RESULTS OF RANDOMIZED TRIALS TO CLINICAL-PRACTICE - IMPACT OF LOSSES BEFORE RANDOMIZATION [J].
CHARLSON, ME ;
HORWITZ, RI .
BRITISH MEDICAL JOURNAL, 1984, 289 (6454) :1281-1284
[3]   Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP-Sponsored Clinical Trials [J].
Cheng, Steven K. ;
Dietrich, Mary S. ;
Dilts, David M. .
CLINICAL CANCER RESEARCH, 2011, 17 (07) :1947-1955
[4]   A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies [J].
Cheng, Steven K. ;
Dietrich, Mary S. ;
Dilts, David M. .
CLINICAL CANCER RESEARCH, 2010, 16 (22) :5557-5563
[5]   US cancer trials may go the way of the Oldsmobile [J].
Dilts, David .
NATURE MEDICINE, 2010, 16 (06) :632-632
[6]   Phase III Clinical Trial Development: A Process of Chutes and Ladders [J].
Dilts, David M. ;
Cheng, Steven K. ;
Crites, Joshua S. ;
Sandler, Alan B. ;
Doroshow, James H. .
CLINICAL CANCER RESEARCH, 2010, 16 (22) :5381-5389
[7]  
Durivage H, 2009, GUID DOC IMPL EFF CA, V27, P6557
[8]  
Durivage HJ, 2009, J CLIN ONCOL, V27
[9]  
Go R, 2010, AM SOC CLIN ONC CHIC
[10]   ACADEMIC MEDICAL-CENTERS UNDER SIEGE [J].
KASSIRER, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (20) :1370-1371